VCR - First US implant

July 18, 2005

Ventracor Limited (ASX: VCR) announced today the first implant in the United States of the VentrAssistTM Left Ventricular Assist System (LVAS).

The procedure was performed by a team led by Professor Bartley P. Griffith, M.D. at the University of Maryland Medical Center in Baltimore. The first US implant of the VentrAssist is part of an FDA-approved feasibility study in 10 patients at up to five hospitals across the United States. The trial is managed in part by the International Center for Health Outcomes and Innovation Research (InCHOIR).

Dr. Griffith said: "We are very pleased to participate in the clinical trial of the VentrAssist, and hope that this new technology will be shown to provide new hope for the thousands of people suffering from end stage heart failure."

Ventracor Limited Chief Executive Officer, Colin Sutton PhD, said: "With each implant, we are adding to the body of clinical evidence and experience. The first VentrAssist implant in the United States was only possible due to the tireless work and dedication of a worldwide team of people in Australia, US and Europe." Dr Sutton noted that to date nearly 30 patients had been implanted with the VentrAssist globally.

Dr. Griffith - is Chief of the Division of Cardiac Surgery and Director of Heart and Lung Transplantation in the Department of Surgery at the University of Maryland Medical Center and is a Professor of Surgery at the University of Maryland School of Medicine. Prior to his arrival at the University of Maryland, Dr. Griffith served as Vice Chair, Department of Surgery at the University of Pittsburgh School of Medicine, where he was also Chief of Cardiothoracic Surgery and the Henry T. Bahnson Professor of Surgery.

Congestive Heart Failure - in the United States, congestive heart failure (CHF) affects about five million people, or two percent of the population. There are an estimated 550,000 new cases diagnosed each year, and around 45,000 deaths from CHF.

Ventracor - is a global medical device company that has developed a blood pump, the VentrAssistTM left ventricular assist system (LVAS) for patients in cardiac failure. The company hopes to bring the VentrAssistTM to the global market in record time, and expects to obtain a significant share of the huge potential market.
For further information, please contact:
Andrew Geddes
Manager, Investor Relations
Ventracor Limited
T: 61-294-063-086

Research Australia

Related Cardiac Surgery Articles from Brightsurf:

New surgical tools with smart sensors can advance cardiac surgery and therapy
Researchers developed a new class of medical instruments equipped with an advanced soft electronics system that could dramatically improve the diagnoses and treatments of a number of cardiac diseases and conditions.

How commonly do patients develop persistent opioid use after cardiac surgery?
A large, national database was used to determine how common it was for patients who hadn't used opioids before undergoing a coronary artery bypass grafting or heart valve procedure to subsequently develop persistent opioid use after surgery.

Preoperative levels of heart proteins may help predict death or cardiac complications in patients undergoing noncardiac surgery
Assessing preoperative levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker of heart stress and structural changes, may improve risk prediction beyond the clinical risk score in patients having noncardiac surgery.

Study finds connection between cardiac blood test before surgery and adverse outcomes
The VISION study looked at whether levels of a cardiac blood test, NT-proBNP, measured before surgery can predict cardiac and vascular complications.

Mayo Clinic study: 20% of patients are prescribed opioids after cardiac device implantation surgery
One in five patients is prescribed opioids after having a pacemaker or similar device implanted, according to a large US study conducted at Mayo Clinic published in HeartRhythm.

Careful monitoring of children following cardiac surgery may improve long-term outcomes
In a medical records study covering thousands of children, a US-Canadian team led by researchers at Johns Hopkins Medicine concludes that while surgery to correct congenital heart disease (CHD) within 10 years after birth may restore young hearts to healthy function.

Chest cavity fire during emergency cardiac surgery
At this year's Euroanaesthesia Congress (the annual meeting of the European Society of Anaesthesiology) in Vienna, Austria (1-3 June), doctors present the unique case of a man who suffered a flash fire in his chest cavity during emergency heart surgery caused by supplemental oxygen leaking from a ruptured lung.

Steroid use during cardiac bypass surgery did not reduce risk of severe kidney injury
Using steroids during cardiopulmonary bypass surgery did not reduce the risk of acute kidney injury in people at increased risk of death, according to a study conducted in 18 countries published in CMAJ (Canadian Medical Association Journal).

Cardiac surgery for patients with persistent opioid use associated with higher rate of complications, increased costs
Persistent use of opioids by patients is a public health concern in the United States but not much is known about the effect of that use on patients undergoing cardiac surgery.

Blood thinner significantly reduces the risk of death after non-cardiac surgery
The study enrolled 1,754 patients in 19 countries, 51 percent of whom were male, with an average age of 70 years.

Read More: Cardiac Surgery News and Cardiac Surgery Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to